Articles related to IMMUNOTHERAPY

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

The ABCDE warning signs help spot melanoma early, so counsel your patients regarding Asymmetry, Border, Color, Diameter, and Evolving (the mole or spot changes in size, shape, or color. It may also start to bleed, itch, or crust).

“Subcutaneous administration offers substantial workflow advantages. It can decrease chair time, reduce dependency on central lines, and allow for faster patient turnover.” – Dr. Aakash Desai

“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”

“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”